摘要
背景:雄激素受体(AR)的适应性上调是激素敏感型前列腺癌(CRPC)向去势耐药型前列腺癌(CRPC)发展过程中最常见的事件。AR信号域达到了新的AR信号导向治疗的主要目标,如阿弗他酮和恩扎鲁塔胺在CRPC患者中的应用。 目的:本文综述了AR靶向治疗的一般机制,重点讨论了AR拷贝数(CN)的作用。我们报道了AR CN的方法和临床应用。组织和液体活检的评估,从而获得关于其作为预测和预后生物标记物的作用的完整信息。 结论:由于肿瘤异质性,CRPC患者的预后变化很大。ARCN对CRPC治疗WIT患者的选择和肿瘤监测有一定的帮助。H.新的抗癌治疗方法,如阿弗他酮和恩扎鲁塔胺。进一步研究AR、CN对这些药物的影响及其与其他预后或预测临床事实的潜在结合。在协调临床试验设计的背景下,ORS是必要的。
关键词: 雄激素受体,AR拷贝数,生物标志物,CRPC,前列腺癌,预后。
图形摘要
Current Cancer Drug Targets
Title:AR Copy Number and AR Signaling-directed Therapies in Castrationresistant Prostate Cancer
Volume: 18 Issue: 9
关键词: 雄激素受体,AR拷贝数,生物标志物,CRPC,前列腺癌,预后。
摘要: Background: Adaptive upregulation of Androgen Receptor (AR) is the most common event involved in the progression from hormone sensitive to Castration-Resistant Prostate Cancer (CRPC). AR signaling remains the main target of new AR signalling-directed therapies such as abiraterone and enzalutamide in CRPC patients.
Objective: In this review, we discuss general mechanisms of resistance to AR-targeted therapies, with a focus on the role of AR Copy Number (CN). We reported methods and clinical applications of AR CN evaluation in tissue and liquid biopsy, thus to have a complete information regarding its role as predictive and prognostic biomarker.
Conclusion: Outcomes of CRPC patients are reported to be highly variable as the consequence of tumor heterogeneity. AR CN could contribute to patient selection and tumor monitoring in CRPC treated with new anti-cancer treatment as abiraterone and enzalutamide. Further studies to investigate AR CN effect to these agents and its potential combination with other prognostic or predictive clinical factors are necessary in the context of harmonized clinical trial design.
Export Options
About this article
Cite this article as:
AR Copy Number and AR Signaling-directed Therapies in Castrationresistant Prostate Cancer, Current Cancer Drug Targets 2018; 18 (9) . https://dx.doi.org/10.2174/1568009617666171122145852
DOI https://dx.doi.org/10.2174/1568009617666171122145852 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets Capillary Electrophoresis–Mass Spectrometry in Metabolomics: The Potential for Driving Drug Discovery and Development
Current Drug Metabolism Benzofuran: A Key Heterocycle - Ring Closure And Beyond
Mini-Reviews in Organic Chemistry Therapeutic Vaccines for Cervical Cancer: Dendritic Cell-Based Immunotherapy
Current Pharmaceutical Design Meridianins: Marine-Derived Potent Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry MiR-509-3-5p-NONHSAT112228.2 Axis Regulates p21 and Suppresses Proliferation and Migration of Lung Cancer Cells
Current Topics in Medicinal Chemistry Characterization of Carbonic Anhydrase Isozyme Specific Inhibition by Sulfamated 2-Ethylestra Compounds
Letters in Drug Design & Discovery Advances and Barriers in Mammalian Cell Encapsulation for Treatment of Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Functionalized Upconversion Nanoparticles: Versatile Nanoplatforms for Translational Research
Current Molecular Medicine Molecular Mechanisms and Potential Treatment Targets for Ovarian Cancer by Analyzing Transcriptional Regulatory Network
Letters in Drug Design & Discovery Synthetic and Biological Vesicular Nano-Carriers Designed for Gene Delivery
Current Pharmaceutical Design Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Epigenetic Effects of Environmental Chemicals on Reproductive Biology
Current Drug Targets Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry An Update on Peptide Drugs for Voltage-Gated Calcium Channels
Recent Patents on CNS Drug Discovery (Discontinued) Decreased Serum Adiponectin Level Affected Clinical Pathological Characteristics of Patients with Gastric Cancer
Current Proteomics HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Evaluation of Pipemidic Acid Derivatives for Potential Antimicrobial Activity Application: <i>In silico</i> Studies on Bioactivity
Letters in Drug Design & Discovery